Vir Biotechnology, Inc. Announces Resignation of Herbert Virgin as Executive Vice President, Research and Chief Scientific Officer, Effective August 31, 2022
July 14, 2022 at 08:34 am EDT
Share
Vir Biotechnology, Inc. announced that Herbert (Skip) Virgin, M.D., Ph.D., notified that he will step down as Executive Vice President, Research and Chief Scientific Officer of the Company effective August 31, 2022.
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
Vir Biotechnology, Inc. Announces Resignation of Herbert Virgin as Executive Vice President, Research and Chief Scientific Officer, Effective August 31, 2022
VIR BIOTECHNOLOGY, INC. 
